Be Sure it's the right choice for her

New study confirms\(^1\) using BD SurePath™ identifies more precursor lesions leading to fewer missed cases of cervical cancer

A comprehensive, independent study representing nearly 6 million samples from over 13 years of data taken from a national screening program concludes that using the BD SurePath™ Liquid-based Pap test results in a:

- 15\% increased risk of invasive cervical cancer when compared to conventional cytology (Statistically significant)
- 19\% reduced risk of invasive cervical cancer when compared to conventional cytology (Not statistically significant)
New study confirms BD SurePath™ performs better than other cytology methods

BD SurePath is associated with lower cervical cancer rates.

Author’s conclusions

Using BD SurePath rather than conventional cytology or ThinPrep as the primary test method was associated with lower cervical cancer rates diagnosed after a normal screening sample.

This strongly suggests that the sensitivity of BD SurePath to detect progressive CIN lesions is higher.

About the Publication

This independent analysis was conducted by Erasmus University Medical Center for the Department of Public Health, Rotterdam, Netherlands.

The analysis was based upon the cancer registry available in the Netherlands and the use of the PALGA database, which is a national registry of all cytology and histology reports related to the detection of cancer, including cervical cancer. It evaluates the clinical significance of the increased detection of Cervical Intraepithelial Neoplasia (CIN) grades 2 and above on the risk of developing cancer between screening periods.


BD, Sparks, MD 21152-0999 USA
800.638.8663

bd.com